...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

Free
Message: Re: IP considerations may prevent RVX from disclosing eGFR data

If a combination with another drug, you take out a patent.

The same way with ABL + Statin had generated a new patent.

Koo

Share
New Message
Please login to post a reply